Published in Nat Commun on February 04, 2016
The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol (2017) 0.77
Stalled DNA Replication Forks at the Endogenous GAA Repeats Drive Repeat Expansion in Friedreich's Ataxia Cells. Cell Rep (2016) 0.76
New Reasons to Pursue the Therapeutic Potential of Synthetic Nucleic Acids for Neurological Diseases. JAMA Neurol (2016) 0.75
Movement disorders: Targeted RNA or BDNF gene transfer protects against frataxin deficiency. Nat Rev Neurol (2016) 0.75
Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias (2017) 0.75
Disruption of Higher Order DNA Structures in Friedreich's Ataxia (GAA)n Repeats by PNA or LNA Targeting. PLoS One (2016) 0.75
Alleviating GAA Repeat Induced Transcriptional Silencing of the Friedreich's Ataxia Gene During Somatic Cell Reprogramming. Stem Cells Dev (2016) 0.75
Translating HDAC inhibitors in Friedrich's ataxia. Expert Opin Orphan Drugs (2016) 0.75
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 7.29
Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature (2008) 5.78
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol (2006) 4.25
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol (2009) 3.47
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell (2012) 2.83
The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet (1998) 2.39
Friedreich ataxia: the clinical picture. J Neurol (2009) 2.28
The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet (2007) 2.22
Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem (1998) 2.19
Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res (2007) 1.94
Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res (2010) 1.74
RNAi factors are present and active in human cell nuclei. Cell Rep (2014) 1.73
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res (2007) 1.63
Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest (2011) 1.54
R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet (2014) 1.46
R-loops induce repressive chromatin marks over mammalian gene terminators. Nature (2014) 1.34
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis (2011) 1.29
Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol Med (2010) 1.25
Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res (2013) 1.24
Friedreich's ataxia: past, present and future. Brain Res Rev (2011) 1.22
Transcription-associated R-loop formation across the human FMR1 CGG-repeat region. PLoS Genet (2014) 1.21
Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev (2011) 1.16
Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet (2014) 1.15
Epigenetic therapy for Friedreich ataxia. Ann Neurol (2014) 1.11
Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucleic Acids Res (2011) 1.10
Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet (2013) 1.08
Import routes and nuclear functions of Argonaute and other small RNA-silencing proteins. Trends Biochem Sci (2014) 1.01
Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. J Neurochem (2013) 1.01
Long non-coding RNA targeting and transcriptional de-repression. Nucleic Acid Ther (2013) 0.98
Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry (2014) 0.96
Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res (2014) 0.90
Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus. Hum Mol Genet (2015) 0.90
Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Hum Mol Genet (2014) 0.86
Importin-β facilitates nuclear import of human GW proteins and balances cytoplasmic gene silencing protein levels. Nucleic Acids Res (2015) 0.85
Clinical neurogenetics: friedreich ataxia. Neurol Clin (2013) 0.84
Friedreich's ataxia--a case of aberrant transcription termination? Transcription (2015) 0.82
Therapeutic strategies in Friedreich's ataxia. Brain Res (2013) 0.82
Epigenetic-based therapies for Friedreich ataxia. Front Genet (2014) 0.82
Mechanisms of transcriptional dysregulation in repeat expansion disorders. Biochem Soc Trans (2014) 0.80
Chromatin changes in the development and pathology of the Fragile X-associated disorders and Friedreich ataxia. Biochim Biophys Acta (2012) 0.80
RNAa in action: from the exception to the norm. RNA Biol (2014) 0.78